Ovarian Cancer
Conditions
Brief summary
The aim of this study is to investigate the efficacy and safety of enucleation of enlarged CPLNs in patients with advanced ovarian cancer.
Detailed description
This is an open-label, single-arm, single-centre clinical trial with a historical control design, designed to assess the difference in median recurrence-free survival (mRFS) between patients with stage III/IV cutaneous ovarian cancer, fallopian tube cancer or primary peritoneal cancer who undergo CPLNs resection and those who do not. The required sample size for the historical control group is 52 patients, and the required sample size for the CPLN resection group is also 52 patients. The study will assess the impact of CPLN resection on recurrence, whilst documenting perioperative safety, observing postoperative overall survival (OS) and changes in patients' postoperative quality of life, and finally analysing technical feasibility.
Interventions
PROCEDURECPLN resection
Diaphragmatic angle lymph node dissection
Sponsors
manxiaxia
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Patients with stage III or IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, where imaging indicates enlarged CPLNs (short axis ≥ 5 mm and/or PET-CT positive) and the short axis is ≤ 1 cm; 2. Residual intra-abdominal tumour measuring ≤ 1 cm following cytoreductive surgery; 3. Women aged 18-70 years who are not pregnant or breastfeeding; 4. ECOG performance status of 0 or 1; 5. Adequate organ function: white blood cell count ≥2.5×10⁹/L and neutrophil count ≥1.5×10⁹/L, haemoglobin ≥ 90 g/L, platelets ≥ 100 × 10⁹/L; serum bilirubin ≤ 1.5 times the upper limit of normal, alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal, aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal; serum creatinine ≤ 1.5 times the normal value, creatinine clearance ≥ 60 ml/min; 6. Expected survival ≥ 6 months; 7. The patient fully understands this study, consents to CPLN resection, voluntarily participates in this clinical trial and has signed the informed consent form.
Exclusion criteria
* 1\. Stage I or II epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer; 2. Residual intra-abdominal tumour \> 1 cm following cytoreductive surgery; 3. Imaging showing CPLNs with a short axis \> 1 cm; 4. Imaging evidence of mediastinal lymph node metastasis outside the CPLNs; 5. Presence of other active malignant tumours within the past 5 years. Excludes locally cured tumours (e.g. basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or in situ breast cancer); 6. Concurrent presence of other severe, uncontrollable medical conditions (including atrial fibrillation, angina pectoris, heart failure, ejection fraction \<50%, uncontrolled hypertension, renal insufficiency, or uncontrolled infections); 7. Any unstable condition or circumstance that may compromise patient safety or compliance; 8. Currently receiving treatment with other anticancer drugs; 9. Refusal to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| RFS | experimental group 17.2 month | From the date of surgery until radiological confirmation of recurrence (RECIST 1.1) or death from any cause; |
| Recurrence-free survival (RFS) | 9-17 month | From the date of surgery until radiological confirmation of recurrence (RECIST 1.1) or death from any cause; |
Countries
China
Contacts
CONTACTLi XIAOSEN
Outcome results
None listed